CXCL4-RNA Complexes Circulate in Systemic Sclerosis and Amplify Inflammatory/Pro-Fibrotic Responses by Myeloid Dendritic Cells.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
30 Dec 2022
Historique:
received: 27 11 2022
revised: 16 12 2022
accepted: 17 12 2022
entrez: 8 1 2023
pubmed: 9 1 2023
medline: 11 1 2023
Statut: epublish

Résumé

CXCL4 is an important biomarker of systemic sclerosis (SSc), an incurable autoimmune disease characterized by vasculopathy and skin/internal organs fibrosis. CXCL4 contributes to the type I interferon (IFN-I) signature, typical of at least half of SSc patients, and its presence is linked to an unfavorable prognosis. The mechanism implicated is CXCL4 binding to self-DNA, with the formation of complexes amplifying TLR9 stimulation in plasmacytoid dendritic cells (pDCs). Here, we demonstrate that, upon binding to self-RNA, CXCL4 protects the RNA from enzymatic degradation. As a consequence, CXCL4-RNA complexes persist in vivo. Indeed, we show for the first time that CXCL4-RNA complexes circulate in SSc plasma and correlate with both IFN-I and TNF-α. By using monocyte-derived DCs (MDDCs) pretreated with IFN-α as a model system (to mimic the SSc milieu of the IFN-I signature), we demonstrate that CXCL4-RNA complexes induce MDDC maturation and increase, in particular, pro-inflammatory TNF-α as well as IL-12, IL-23, IL-8, and pro-collagen, mainly in a TLR7/8-dependent but CXCR3-independent manner. In contrast, MDDCs produced IL-6 and fibronectin independently in their CXCL4 RNA-binding ability. These findings support a role for CXCL4-RNA complexes, besides CXCL4-DNA complexes, in immune amplification via the modulation of myeloid DC effector functions in SSc and also during normal immune responses.

Identifiants

pubmed: 36614095
pii: ijms24010653
doi: 10.3390/ijms24010653
pmc: PMC9820649
pii:
doi:

Substances chimiques

Angiogenesis Inhibitors 0
Immunologic Factors 0
Interferon-alpha 0
Platelet Factor 4 37270-94-3
RNA 63231-63-0
Tumor Necrosis Factor-alpha 0
PF4 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : FOREUM research grant
ID : 2020-2023

Références

J Cell Mol Med. 2020 Dec;24(23):13600-13608
pubmed: 33157566
J Cell Physiol. 2018 Mar;233(3):2409-2419
pubmed: 28731277
Eur J Immunol. 2001 Nov;31(11):3388-93
pubmed: 11745357
Int J Mol Sci. 2020 Jul 19;21(14):
pubmed: 32707718
J Immunol. 2007 May 15;178(10):6208-16
pubmed: 17475848
Nat Commun. 2019 May 1;10(1):1731
pubmed: 31043596
Nat Rev Rheumatol. 2019 May;15(5):288-302
pubmed: 30953037
Nat Rev Rheumatol. 2014 Jul;10(7):390-402
pubmed: 24752182
J Exp Med. 2001 Sep 17;194(6):863-9
pubmed: 11561001
Arthritis Rheum. 2008 Jul;58(7):2163-73
pubmed: 18576347
Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L127-L136
pubmed: 28860143
J Exp Med. 1994 Apr 1;179(4):1109-18
pubmed: 8145033
Front Immunol. 2020 Sep 17;11:2149
pubmed: 33042127
J Rheumatol. 2000 Dec;27(12):2838-42
pubmed: 11128673
Eur J Immunol. 2002 Jul;32(7):1958-68
pubmed: 12115616
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
Ann Rheum Dis. 2016 Aug;75(8):1567-73
pubmed: 26371289
Nature. 1998 Mar 19;392(6673):245-52
pubmed: 9521319
Cytokine Growth Factor Rev. 2011 Feb;22(1):1-18
pubmed: 21111666
J Exp Med. 1994 Jul 1;180(1):83-93
pubmed: 8006603
J Innate Immun. 2018;10(5-6):398-406
pubmed: 30404092
J Breath Res. 2016 Nov 21;10(4):046013
pubmed: 27869103
Lancet. 2017 Oct 7;390(10103):1685-1699
pubmed: 28413064
J Immunol. 2017 Jul 1;199(1):253-262
pubmed: 28515281
J Pathol. 2008 Jan;214(2):149-60
pubmed: 18161752
J Immunol. 2002 May 1;168(9):4531-7
pubmed: 11970999
Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):186-192
pubmed: 27385265
Am J Physiol Lung Cell Mol Physiol. 2003 Apr;284(4):L566-77
pubmed: 12618418
Adv Drug Deliv Rev. 2017 Nov 1;121:43-56
pubmed: 28736303
Semin Immunopathol. 2015 Sep;37(5):543-57
pubmed: 26152640
Front Immunol. 2013 Sep 06;4:266
pubmed: 24046769
Science. 1998 Oct 16;282(5388):480-3
pubmed: 9774276
Autoimmunity. 2018 Feb;51(1):1-9
pubmed: 29256263
Ann Rheum Dis. 2016 Aug;75(8):1521-6
pubmed: 26338038
Autoimmun Rev. 2011 Mar;10(5):267-75
pubmed: 20863909
Immunotherapy. 2014;6(3):283-9
pubmed: 24762073
Rheumatology (Oxford). 2019 Sep 1;58(9):1534-1546
pubmed: 31292645
N Engl J Med. 2014 Jan 30;370(5):433-43
pubmed: 24350901
Immunology. 2018 May;154(1):3-20
pubmed: 29313948
Arthritis Res. 2002;4 Suppl 3:S233-42
pubmed: 12110143
J Rheumatol. 2008 Jan;35(1):120-5
pubmed: 18085738
Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(4):274-284
pubmed: 32476963
Clin Exp Immunol. 2020 Jul;201(1):14-24
pubmed: 32048277

Auteurs

Immacolata Pietraforte (I)

Istituto Superiore di Sanità, Department of Oncology and Molecular Medicine, 00161 Rome, Italy.

Alessia Butera (A)

Istituto Superiore di Sanità, National Center for Drug Research and Evaluation, 00161 Rome, Italy.

Lucia Gaddini (L)

Istituto Superiore di Sanità, National Center for Drug Research and Evaluation, 00161 Rome, Italy.

Anna Mennella (A)

Istituto Superiore di Sanità, National Center for Drug Research and Evaluation, 00161 Rome, Italy.

Raffaella Palazzo (R)

Istituto Superiore di Sanità, National Center for Drug Research and Evaluation, 00161 Rome, Italy.

Doriana Campanile (D)

Istituto Superiore di Sanità, National Center for Drug Research and Evaluation, 00161 Rome, Italy.

Katia Stefanantoni (K)

Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Roma, Italy.

Valeria Riccieri (V)

Department of Clinical, Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, 00185 Roma, Italy.

Roberto Lande (R)

Istituto Superiore di Sanità, National Center for Drug Research and Evaluation, 00161 Rome, Italy.

Loredana Frasca (L)

Istituto Superiore di Sanità, National Center for Drug Research and Evaluation, 00161 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH